Major depressive disorder increased risk of psoriasis: A propensity score matched cohort study

2021 ◽  
Vol 278 ◽  
pp. 407-412 ◽  
Author(s):  
Yi-Hsien Chen ◽  
Wei-Ming Wang ◽  
I-Hsun Li ◽  
Hui-Han Kao ◽  
Chin-Bin Yeh ◽  
...  
PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46818 ◽  
Author(s):  
Cheng-Ta Li ◽  
Ya-Mei Bai ◽  
Pei-Chi Tu ◽  
Ying-Chiao Lee ◽  
Yu-Lin Huang ◽  
...  

2018 ◽  
Vol 50 (7) ◽  
pp. 605-612 ◽  
Author(s):  
Chia-Wen Lu ◽  
Yu-Kang Chang ◽  
Yi-Hsuan Lee ◽  
Chia-Sheng Kuo ◽  
Hao-Hsiang Chang ◽  
...  

2021 ◽  
Author(s):  
Min-Kyung Lee ◽  
Bongsung Kim ◽  
Kyungdo Han ◽  
Jae-Hyuk Lee ◽  
Minhee Kim ◽  
...  

<b>OBJECTIVE</b><b></b> <p>To assess the association between use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea.</p> <p><b>RESEARCH DESIGN AND METHODS</b><b></b></p> <p>We used an active comparator, new user design and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47 369 new users of SGLT2 inhibitors and 47 369 users of other glucose-lowering drugs (oGLD). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken.</p> <p><b>RESULTS</b></p> <p>During the follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1000 person-years in patients treated with SGLT2 inhibitors and oGLD, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264, 95% CI 1.056–1.513). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for <em>age and estimated glomerular filtration rate (eGFR);</em> the HR for RVO was higher in patients aged ≥ 60 years and those with eGFR <60 mL/min/1.73m<sup>2</sup> than in others.</p> <p><b>CONCLUSIONS</b></p> <p>In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. The older patients and those with chronic kidney disease were at higher risk for RVO. </p>


2021 ◽  
Author(s):  
Min-Kyung Lee ◽  
Bongsung Kim ◽  
Kyungdo Han ◽  
Jae-Hyuk Lee ◽  
Minhee Kim ◽  
...  

<b>OBJECTIVE</b><b></b> <p>To assess the association between use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea.</p> <p><b>RESEARCH DESIGN AND METHODS</b><b></b></p> <p>We used an active comparator, new user design and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47 369 new users of SGLT2 inhibitors and 47 369 users of other glucose-lowering drugs (oGLD). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken.</p> <p><b>RESULTS</b></p> <p>During the follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1000 person-years in patients treated with SGLT2 inhibitors and oGLD, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264, 95% CI 1.056–1.513). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for <em>age and estimated glomerular filtration rate (eGFR);</em> the HR for RVO was higher in patients aged ≥ 60 years and those with eGFR <60 mL/min/1.73m<sup>2</sup> than in others.</p> <p><b>CONCLUSIONS</b></p> <p>In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. The older patients and those with chronic kidney disease were at higher risk for RVO. </p>


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kuang-Tsu Yang ◽  
Sin-Ei Juang ◽  
Yao-Min Hung ◽  
James Cheng-Chung Wei ◽  
Hei-Tung Yip ◽  
...  

AbstractNontyphoidal salmonella (NTS) infection has a high mortality rate. Bowel resections affect gut microbiota and immune function, and the association between bowel resection and NTS infection in human beings has not been addressed. We conducted a nationwide propensity score (PS)-matched cohort study to clarify this association. Data from the Longitudinal Health Insurance Database of Taiwan were used to establish a case-cohort with bowel resections from 2000 to 2013. Informed consent was waived by the Institutional Review Board of China Medical University Hospital (CMUH104-REC2-115) because all personal identifying information used had been de-identified. Each case was matched with one control without any bowel resection according to age, gender, index date, and propensity score (PS). Cumulative incidences of and hazard ratios (HRs) for NTS infection development were analyzed. The incidence of NTS infection was greater in patients with a bowel resection than in the control group (2.97 vs. 1.92 per 10,000 person-years), with an adjusted hazard ratio (aHR) of 1.64 (95% CI = 1.08–2.48). The incidence of NTS infection increased significantly for cases with small bowel resections and right hemicolectomies. Age (31–40 and > 50 years), hypertension, chronic kidney disease, chronic obstructive pulmonary disease, and autoimmune diseases were significant risk factors of NTS infection. Stratification analysis revealed that patients without comorbidities were prone to NTS infection after bowel resections. The increased risk of developing NTS infection could be related to the bowel resection. Specific age groups and comorbidities also contribute to increased risk of NTS infection.


Sign in / Sign up

Export Citation Format

Share Document